Abstract
Cost-effectiveness analysis (CEA) represents the most important tool in the health economics literature to quantify and qualify the reasoning behind the optimal decision process in terms of the allocation of resources to a given health intervention. However, the practical application of CEA in regulatory process is often limited by some critical barriers, and decisions in clinical practice are frequently influenced by factors that do not contribute to an efficient resources allocation, leading to inappropriate drug prescription and utilisation. Moreover, most of the times there is uncertainty about the real cost-effectiveness profile of an innovative intervention, with the consequence that it is usually impossible to obtain an immediate and perfect substitution of an intervention with another having a better cost-effectiveness ratio. We propose a rational approach to CEA within regulatory processes basing our analysis in a Bayesian decision-theoretic framework and proposing an extension of the application of well known tools (such as the expected value of information) to such cases. The regulator can use these tools to identify the economic value of reducing the uncertainty surrounding the cost-effectiveness profile of the several alternatives. This value can be compared to the one that is generated by the actual combination (in terms of market shares) of different options: one that is the most cost-effective and others in the same therapeutic category that, despite producing clinical benefits, are less cost-effective. We use prescription of statins as a case study.
Highlights
Cost-effectiveness analysis (CEA) represents the most important tool in the health economics literature to quantify and qualify the reasoning behind the optimal decision process in terms of the allocation of resources to a given health intervention
The practical application of CEA in regulatory process is often limited by some critical barriers, and decisions in clinical practice are frequently influenced by factors that do not contribute to an efficient resources allocation, leading to inappropriate drug prescription and utilisation
We propose a rational approach to CEA within regulatory processes basing our analysis in a Bayesian decision-theoretic framework and proposing an extension of the application of well known tools to such cases
Summary
Cost-effectiveness analysis (CEA) represents the most important tool in the health economics literature to quantify and qualify the reasoning behind the optimal decision process in terms of the allocation of resources to a given health intervention. Expected value of information in the case of mixed strategies From 2nd Clinical Trials Methodology Conference: Methodology Matters Edinburgh, UK.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.